|
Your experience with pancreatic cancer can help. Share your voice. Take a survey that is open to all pancreatic cancer patients and survivors, as well as those who have served as caregivers. Canadian approval of Abraxane is being considered for the treatment of advanced pancreatic cancer. Your input with pancreatic cancer, past and present, is a key element in making recommendations for new drugs. Abraxane works by delaying tumor growth. Abraxane is intended to be used with gemcitabine, another chemotherapy drug, in patients with pancreatic cancer that has spread to other parts of the body. It was initially approved in 2005 for breast cancer and is also approved for non-small cell lung cancer. Abraxane, created by Celgene, is now approved by the Food and Drug Administration (FDA) in the United States and last week, was approved by the European Union (EU) to be part of a chemotherapy regimen to fight late-stage pancreatic cancer. Thank you for your willingness to contribute. |
|
Click here to view this message as HTML in your browser. |
